Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acalabrutinib, Venetoclax and Durvalumab in Richter Transformation From CLL
NCT05388006Phase 2Active, not recruiting
- Sponsor
- Mayo Clinic
- Start
- Jan 2023
- Primary completion
- Sep 2026
- Modality
- Antibody Conjugates, Small Molecules, Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of acalabrutinib tablet (Variant 1), venetoclax and durvalumab in Richter syndrome (RS), sponsored by Mayo Clinic. Primary endpoint: Progression-Free Survival at 6 months. Started Jan 2023; status: active, not recruiting.
02
Drugs
acalabrutinib tablet (Variant 1)venetoclaxdurvalumab
03
Conditions
Richter syndrome (RS)
Beyond the preview
Go deeper on NCT05388006.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05388006.